Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Net Income (2016 - 2025)

Cytokinetics (CYTK) has disclosed Net Income for 16 consecutive years, with -$233.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income changed N/A to -$233.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$389.1 million, a N/A change, with the full-year FY2025 number at -$657.8 million, down 14.62% from a year prior.
  • Net Income was -$233.5 million for Q4 2025 at Cytokinetics, down from -$155.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$13.7 million in Q2 2022 to a low of -$233.5 million in Q4 2025.
  • A 5-year average of -$110.9 million and a median of -$129.4 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: plummeted 6173.01% in 2021, then surged 76.76% in 2022.
  • Cytokinetics' Net Income stood at -$25.9 million in 2021, then plummeted by 417.27% to -$134.1 million in 2022, then dropped by 0.37% to -$134.6 million in 2023, then fell by 11.25% to -$149.7 million in 2024, then crashed by 55.96% to -$233.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Net Income are -$233.5 million (Q4 2025), -$155.6 million (Q1 2025), and -$149.7 million (Q3 2024).